MaaT Pharma is planning to first target the European market with MaaT013 for acute graft-versus-host disease with gastrointestinal involvement (GI-aGVHD) as it seeks to raise money to bring its microbiome-based drug to the US market.
The Lyon, France-based biotech company announced 8 January data from the single-arm, open-label Phase III ARES trial, testing the drug...